Illumina (ILMN) Shares Slammed as Roche (RHHBY) to Drop $51/Share Bid
Tweet
Share
E-mail
Get Alerts ILMN Hot Sheet
Join SI Premium – FREE
Illumina (Nasdaq: ILMN) shares are sinking Wednesday morning following an earlier announcement Roche (OTCBB: RHHBY) will not extend its $51 per share tender offer for the company past the April 20th deadline.
Roche initiated a bid for the company on January 24th at $44.50 per share.
Roche CEO Severin Schwan said, "We continue to hold Illumina and its management in very high regard but, with access only to public information about Illumina’s business and prospects, we do not believe that a price above Roche’s offer for Illumina of $51.00 per share would be in the interest of Roche’s shareholders...Roche will continue to consider options and opportunities to develop further its portfolio of businesses in order to expand its diagnostics leadership position."
Illumina shares are down 8 percent to $40.45 in early trading.
Roche initiated a bid for the company on January 24th at $44.50 per share.
Roche CEO Severin Schwan said, "We continue to hold Illumina and its management in very high regard but, with access only to public information about Illumina’s business and prospects, we do not believe that a price above Roche’s offer for Illumina of $51.00 per share would be in the interest of Roche’s shareholders...Roche will continue to consider options and opportunities to develop further its portfolio of businesses in order to expand its diagnostics leadership position."
Illumina shares are down 8 percent to $40.45 in early trading.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Snap One (SNPO) soars 30% as Resideo acquires smart home product maker for $821m
- Barnes & Noble Education (BNED) Enters Definitive Agreement with Immersion (IMMR)
- M&T Bank (MTB) shares climb as Q1 2024 earnings meet expectations
Create E-mail Alert Related Categories
Mergers and Acquisitions, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
